期刊文献+

沉默S100A10基因对卵巢癌SKOV-3和A2780细胞周期的影响 被引量:2

Effect of Silencing S100A10 Gene on Cell Cycle of Ovarian Cancer SKOV-3 and A2780 Cells
下载PDF
导出
摘要 目的探讨沉默S100钙结合蛋白A10(S100A10)对卵巢癌SKOV-3和A2780细胞周期的影响及其相关分子机制。方法将针对S100A10基因的shRNA转染至SKOV-3和A2780细胞中,获S100A10敲降稳转SKOV-3和A2780细胞系,采用CCK8方法检测细胞增殖能力,采用流式细胞技术检测细胞周期变化,并用Western blot技术检测细胞周期相关的因子CyclinD1、CDK2及CDK4蛋白表达水平的变化。结果S100A10基因敲降后,细胞增殖能力明显减弱(P<0.05),细胞周期阻滞在G_(0)/G_(1)期(P<0.05),细胞周期相关蛋白(CyclinD1、CDK2及CDK4)表达明显下调(P<0.05)。结论S100A10在卵巢癌中作为一个癌基因可以影响肿瘤细胞的增殖。 Objective To explore the effect of silencing S100A10 via shRNA on cell cycle of ovarian cancer SKOV-3 and A2780 cells and the related molecular mechanism.Methods Lentiviral vector mediated transfection was used to scilencing S100A10 in ovarian cancer SKOV-3 and A2780 cells.Then,we obtained S100A10 stable knock-down SKOV-3 and A2780 cell lines.Next,cell counting kit-8(CCK-8)assay,Western blot assay and fluorescence activating cell sorter(FACS)were used to detected cell proliferation,cell cycle and the expression level of cell cycle related factor(CyclinD1,CDK2 and CDK4).Results The results of CCK8 assay indicated that after S100A10 knockdown,the proliferation ability of shS100A10 groups were significantly lower than the control group(P<0.05).The results of flow cytometry showed that the G_(0)/G_(1)ratio in the shS100A10 groups were significantly higher than the control group(P<0.05).The expression of cell cycle related factor was decreased in shS100A10 groups compared with the control group(P<0.05).Conclusion S100A10 may be an oncogene in ovarian cancer.
作者 颜伟 陈潭琇 王雅琦 王灵芝 YAN Wei;CHEN Tanxiu;WANG Yaqi(Jiangxi Cancer Hospital,Nanchang,330029)
出处 《实用癌症杂志》 2021年第4期532-535,539,共5页 The Practical Journal of Cancer
基金 江西省卫生健康委科技计划(编号:20203546) 江西省中医药科研课题(编号:2019B112)。
关键词 S100A10 卵巢癌 细胞周期 细胞周期相关因子 S100A10 Ovarian cancer Cell cycle Cell cycle related factor
  • 相关文献

参考文献4

二级参考文献42

  • 1汤参娥,李萃,肖志强,章晓鹏,陈主初,易红,李建玲,段朝军,梁宋平.人肺鳞癌组织的比较蛋白质组学研究[J].中华肿瘤杂志,2006,28(4):274-279. 被引量:14
  • 2Chen EY,Mehra K,Mehrad M,et al.Secretory cell outgrowth,PAX2 and serous carcinogenesis in the Fallopian tube[J].J Pathol,2010,222(1):110-116.
  • 3Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
  • 4Mei L,Chen H,Wei DM,et al.Maintenance chemotherapy for ovarian cancer[J].Cochrane Database Syst Rev,2010,9:D7414.
  • 5Heintz AP,Odicino F,Maisonneuve P,et al.Carcinoma of the ovary.FIGO 26th annual report on the results of treatment in gynecological cancer[J].Int J Gynaecol Obstet,2006,95(Suppl 1):S161-S192.
  • 6Aletti GD,Gallenberg MM,Cliby WA,et al.Current management strategies for ovarian cancer[J].Mayo Clin Proc,2007,82(6):751-770.
  • 7Clarke-Pearson DL.Clinical practice.screening for ovarian cancer[J].N Engl J Med,2009,361(2):170-177.
  • 8Zamore PD,Haley B.Ribognome:the big world of small RNAs[J].Science,2005,309:1519-1524.
  • 9Li J,Fadare O,Xiang L,et al.Ovarian serous carcinoma:recent concepts on its origin and carcinogenesis[J].J Hematol Oncol,2012,5(1):8-19.
  • 10Liu Z,Liu J,Segura MF,et al.MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma[J].J Pathol,2012,228(2):204-215.

共引文献9

同被引文献22

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部